Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page now displays the clinical trial record, including its study design, eligibility criteria, locations, outcomes, and supporting documents, rather than a 403 error message.SummaryDifference100%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe EV-302 study record page now renders a 403 Forbidden error, replacing the usual study content with a minimal error screen. The page shows a Home button instead of the detailed study information.SummaryDifference17%

Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.